CytomX Therapeutics, Inc. Debt Securities, Available-for-sale
CytomX Therapeutics, Inc. (CTMX) had Debt Securities, Available-for-sale of $336.27 million as of 2018-09-30, per its 10-Q filed 2018-11-06.
Discontinued › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2018-11-06
- 2018-09-30: Debt Securities, Available-for-sale $336.27M.
- 2018-06-30: Debt Securities, Available-for-sale $334.61M.
- 2018-03-31: Debt Securities, Available-for-sale $351.12M.
- 2017-12-31: Debt Securities, Available-for-sale $361.92M.
| Period end | Debt Securities, Available-for-sale | Debt Securities, Available-for-sale as first filed |
|---|---|---|
| 2018-09-30 | $336.27M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $334.61M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $351.12M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $361.92M 10-Q · filed 2018-11-06 | |
| 2017-09-30 | $321.19M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $63.06M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $76.86M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $167.84M 10-K · filed 2018-03-07 | $77.29M 10-K · filed 2017-03-02 |
| 2016-09-30 | $120.73M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $133.42M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $112.74M 10-Q · filed 2016-05-06 | |
| 2015-12-31 | $126.89M 10-K · filed 2017-03-02 | |
| 2015-09-30 | $77.50M 10-Q · filed 2015-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |